Q2 2026 Biotricity Inc Earnings Call Transcript
Key Points
- Biotricity Inc (BTCY) reported a 19% increase in revenue for the second quarter of fiscal 2026, reaching $3.9 million, driven by strong market adoption of their Technology-as-a-Service subscription model.
- The company achieved a gross profit of $3.2 million, up 29.4% from the prior year, with a gross profit percentage improvement of 660 basis points to 81.9%.
- Biotricity Inc (BTCY) has achieved positive EBITDA for the second consecutive quarter, with $373,000 reported this quarter, indicating progress towards full profitability.
- The company is expanding its market presence through strategic partnerships, including contracts with the VA and leading home care groups, and is actively pursuing geographic expansion.
- Biotricity Inc (BTCY) is focused on innovation, with ongoing development of next-generation diagnostic technologies, including the Biocore Pro 2 cardiac monitor, which is expected to be filed for FDA approval by the end of Q1 next year.
- Despite improvements, Biotricity Inc (BTCY) reported a net loss attributable to common shareholders of $772,000 for the fiscal 3-month period.
- Operating expenses increased by 5.1% to $2.9 million compared to the same period last year, with SG&A expenses rising by 2.5%.
- The company is still in the process of achieving full profitability, with a focus on scaling the business and investing in commercial expansion.
- Biotricity Inc (BTCY) faces the challenge of maintaining margins while scaling operations and expanding its commercial team.
- The company is reliant on the successful commercialization of its Biocore, Bioflux, and Biocare products to drive future growth and profitability.
Good afternoon, and welcome to Biotricity's second quarter fiscal 2026 financial results and business update conference call. Today's conference is being recorded. As a reminder, this is Biotricity's second quarter fiscal 2026 ended on September 30, 2025.
So all figures presented for this period will reflect that end date. Earlier, Biotricity issued its earnings press release for the period, which highlighted financial and operational results. A copy of the press release is available on the Investor Relations section of Biotricity's website and full financials have been filed with the SEC on Form 10-Q and posted on EDGAR at www.sec.gov.
Before beginning the company's formal remarks, I'd like to remind the listeners that today's discussions may contain forward-looking statements that reflect management's current views with respect to future events. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. Biotricity
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
